These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 27736953)

  • 1. Projected Uptake of New Antiretroviral (ARV) Medicines in Adults in Low- and Middle-Income Countries: A Forecast Analysis 2015-2025.
    Gupta A; Juneja S; Vitoria M; Habiyambere V; Nguimfack BD; Doherty M; Low-Beer D
    PLoS One; 2016; 11(10):e0164619. PubMed ID: 27736953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries.
    Waning B; Diedrichsen E; Moon S
    J Int AIDS Soc; 2010 Sep; 13():35. PubMed ID: 20840741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.
    Nunn AS; Fonseca EM; Bastos FI; Gruskin S; Salomon JA
    PLoS Med; 2007 Nov; 4(11):e305. PubMed ID: 18001145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?
    Vitoria M; Hill A; Ford N; Doherty M; Clayden P; Venter F; Ripin D; Flexner C; Domanico PL
    AIDS; 2018 Jul; 32(12):1551-1561. PubMed ID: 29746295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
    Venter WDF; Moorhouse M; Sokhela S; Fairlie L; Mashabane N; Masenya M; Serenata C; Akpomiemie G; Qavi A; Chandiwana N; Norris S; Chersich M; Clayden P; Abrams E; Arulappan N; Vos A; McCann K; Simmons B; Hill A
    N Engl J Med; 2019 Aug; 381(9):803-815. PubMed ID: 31339677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The HIV Treatment Gap: Estimates of the Financial Resources Needed versus Available for Scale-Up of Antiretroviral Therapy in 97 Countries from 2015 to 2020.
    Dutta A; Barker C; Kallarakal A
    PLoS Med; 2015 Nov; 12(11):e1001907; discussion e1001907. PubMed ID: 26599990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical Equivalence of Distributed Generic Antiretroviral (ARV) in Asian Settings: The Cross-Sectional Surveillance Study - PEDA Study.
    Sapsirisavat V; Vongsutilers V; Thammajaruk N; Pussadee K; Riyaten P; Kerr S; Avihingsanon A; Phanuphak P; Ruxrungtham K;
    PLoS One; 2016; 11(6):e0157039. PubMed ID: 27322409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Forecasting the global demand for HIV monitoring and diagnostic tests: A 2016-2021 analysis.
    Habiyambere V; Dongmo Nguimfack B; Vojnov L; Ford N; Stover J; Hasek L; Maggiore P; Low-Beer D; Pérez Gonzàlez M; Edgil D; Williams J; Kuritsky J; Hargreaves S; NeSmith T
    PLoS One; 2018; 13(9):e0201341. PubMed ID: 30231022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What strategies to boost production of affordable fixed-dose anti-retroviral drug combinations for children in the developing world?
    Dionisio D; Gass R; McDermott P; Racalbuto V; Madeo M; Braghieri G; Crowley S; Pinheiro Edos S; Graaff P; Vasan A; Eksaengsri A; Moller H; Khanna AK; Kraisintu K; Juneja S; Nicolaou S; Sengupta A; Esperti F; Messeri D
    Curr HIV Res; 2007 Mar; 5(2):155-87. PubMed ID: 17346132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends and economic stress: a challenge to universal access to antiretroviral treatment in India.
    Dhamija P; Bansal D; Medhi B
    Curr HIV Res; 2009 Jul; 7(4):410-7. PubMed ID: 19601776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The global pediatric antiretroviral market: analyses of product availability and utilization reveal challenges for development of pediatric formulations and HIV/AIDS treatment in children.
    Waning B; Diedrichsen E; Jambert E; Bärnighausen T; Li Y; Pouw M; Moon S
    BMC Pediatr; 2010 Oct; 10():74. PubMed ID: 20950492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can the generic antiretroviral industry support access to a universal antiretroviral regimen?
    Amole CD; Middlecote C; Prabhu VR; Kumarasamy N
    Curr Opin HIV AIDS; 2017 Jul; 12(4):390-397. PubMed ID: 28441147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Projected savings through public health voluntary licences of HIV drugs negotiated by the Medicines Patent Pool (MPP).
    Juneja S; Gupta A; Moon S; Resch S
    PLoS One; 2017; 12(5):e0177770. PubMed ID: 28542239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active pharmaceutical ingredients for antiretroviral treatment in low- and middle-income countries: a survey.
    Fortunak JM; de Souza RO; Kulkarni AA; King CL; Ellison T; Miranda LS
    Antivir Ther; 2014; 19 Suppl 3(0 3):15-29. PubMed ID: 25310430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs.
    Holmes CB; Coggin W; Jamieson D; Mihm H; Granich R; Savio P; Hope M; Ryan C; Moloney-Kitts M; Goosby EP; Dybul M
    JAMA; 2010 Jul; 304(3):313-20. PubMed ID: 20639565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors influencing global antiretroviral procurement prices.
    Wirtz VJ; Forsythe S; Valencia-Mendoza A; Bautista-Arredondo S
    BMC Public Health; 2009 Nov; 9 Suppl 1(Suppl 1):S6. PubMed ID: 19922690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretrovirals for low income countries: an analysis of the commercial viability of a highly competitive market.
    Nakakeeto ON; Elliott BV
    Global Health; 2013 Feb; 9():6. PubMed ID: 23410145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-savings and potential cost-savings through the distribution of generic antiretroviral drugs within the statutory health insurance market of Germany between January 2017 and June 2019.
    Lottes M; Bremer V; Prugger C; Kollan C; Schmidt D
    BMC Health Serv Res; 2022 Jan; 22(1):63. PubMed ID: 35027062
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.